Fri.Mar 24, 2023

article thumbnail

StartUPDATES: New Developments from Healthcare Startups

MedCity News

Check out news from OUI Medical, Vital, Cognito Therapeutics and Reveal HealthTech.

article thumbnail

Sanofi, Regeneron's Dupixent could hit $20B in peak sales with COPD expansion: analyst

Fierce Pharma

Sanofi, Regeneron's Dupixent could hit $20B in peak sales with COPD expansion: analyst kdunleavy Fri, 03/24/2023 - 07:30

Sales 253
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Celebrating Women in Health Care Starts with Reimagining your Workforce

MedCity News

These are challenging times for health care, and particularly for women in health care.

307
307
article thumbnail

What would you fix with a ‘magic wand’? Pharma leaders chime in about clinical trials

PharmaVoice

How life science execs would transform clinical trials with a little hocus pocus.

Pharma 246
article thumbnail

The Intersection of AI and Sales: Personalization Without Compromise

Speaker: Jesse Hunter and Brynn Chadwick

Today’s buyers expect more than generic outreach–they want relevant, personalized interactions that address their specific needs. For sales teams managing hundreds or thousands of prospects, however, delivering this level of personalization without automation is nearly impossible. The key is integrating AI in a way that enhances customer engagement rather than making it feel robotic.

article thumbnail

Biotech Financing Roundup: Mbiomics, Flare Therapeutics, EpiBiologics & More

MedCity News

Flare Therapeutics, EpiBiologics, and Mbiomics are among the biotech companies that recently unveiled new rounds of financing.

Biopharma 290

More Trending

article thumbnail

Oak Street, Interwell Combine Primary Care & Dialysis with New Joint Venture

MedCity News

Oak Street Health teamed up with kidney care management company Interwell Health to create a joint venture called OakWell, which seeks to provide primary care to end-stage kidney disease patients directly in existing dialysis centers. End stage kidney disease patients spend upwards of 12 hours per week in dialysis centers — OakWell is meant to eliminate the barrier of attending separate, additional medical appointments.

article thumbnail

Brii Bio shelves once-promising COVID antibody combo that stood up to variants

Fierce Pharma

Brii Bio shelves once-promising COVID antibody combo that stood up to variants kdunleavy Fri, 03/24/2023 - 10:07

198
198
article thumbnail

SXSW 2023: Moving from NFTs to LSD

PM360

Technology evolves fast. Nothing illustrates that better than attending SXSW each year and noticing how much has changed in just 12 months. In 2022, SXSW was all NFTs and metaverse activations and events, and in 2023 they weren’t anywhere to be found. But a lot was shared at this year’s SXSW that had staying power. In place of NFTs, psychedelics were given their own conference track this year.

Media 119
article thumbnail

Time to pay Daniel O'Day: Gilead chief nabbed nearly $22M after strong showings in HIV, cancer

Fierce Pharma

Time to pay Daniel O'Day: Gilead chief nabbed nearly $22M after strong showings in HIV, cancer fkansteiner Fri, 03/24/2023 - 08:56

165
165
article thumbnail

5 Ways You Can Win Faster with Gen AI in Sales

Incorporating generative AI (gen AI) into your sales process can speed up your wins through improved efficiency, personalized customer interactions, and better informed decision- making. Gen AI is a game changer for busy salespeople and can reduce time-consuming tasks, such as customer research, note-taking, and writing emails, and provide insightful data analysis and recommendations.

article thumbnail

Developing novel therapies for NASH

European Pharmaceutical Review

Following the recent announcement of topline results from 89bio’s Phase IIb trial, ENLIVEN, evaluating FGF21 analogue pegozafermin for nonalcoholic steatohepatitis (NASH), a serious liver condition, EPR spoke with Dr Hank Mansbach, the company’s Chief Medical Officer. NASH currently has no approved treatments. Caused by excess fat, it is referred to as the ‘silent killer’, as most affected individuals don’t exhibit symptoms until liver damage has already occurred.

Medical 108
article thumbnail

With rejection for slow-release Jakafi, FDA sends shockwaves across Incyte's pipeline: analyst

Fierce Pharma

With rejection for slow-release Jakafi, FDA sends shockwaves across Incyte's pipeline: analyst aliu Fri, 03/24/2023 - 10:04

FDA 147
article thumbnail

Destiny releases pivotal phase 2 data involving XF-73 nasal gel

PharmaTimes

Study shows significant reduction of nasal S.

Patients 104
article thumbnail

At London Book Fair, Spotlight on Ukraine

Copyright Clearance Center

The post At London Book Fair, Spotlight on Ukraine appeared first on Copyright Clearance Center.

98
article thumbnail

AI in Marketing & Sales: Today’s Tools, Tomorrow’s Potential

Speaker: Kevin Burke

AI is reshaping marketing and sales, empowering professionals to work smarter, faster, and more effectively. This webinar will provide a practical introduction to AI, focusing on its current applications, transformative potential, and strategies for successful implementation in your organization. Using real-world examples and actionable insights, we’ll examine how businesses are leveraging AI to increase efficiency, enhance personalization, and drive measurable results.

article thumbnail

2023 PM Society Awards – Winners Announced

PharmaTimes

21GRAMS takes four Golds plus Best in Show AstraZeneca tops the pharma leader board

Pharma 104
article thumbnail

Cancer Patient-Support Program Uptake is Low: Here’s How to Change That

PM360

Cancer-support programs provide vital assistance to patients and their caregivers as they face one of the toughest times of their lives. Yet while patients are interested in these programs, new survey data suggests they aren’t taking advantage of them. Results from 825 patients diagnosed with or treated for cancer who were surveyed on Phreesia’s PatientInsights platform as they checked in for their doctors’ appointments revealed that few cancer patients are accessing the support resources availa

article thumbnail

Debiopharm reveals phase 1/2 GaLuCi research results

PharmaTimes

The multi-centre international clinical trial will evaluate company’s Debio 0328 candidate

99
article thumbnail

4 Steps to Create an Inclusive Workplace by Overcoming Personal Biases

PM360

Unacknowledged personal biases in the workplace can quickly spiral, leaving employees feeling alienated and disengaged. This has far-reaching implications that can also influence external brand experiences with target stakeholders. In the healthcare industry, this is especially concerning as it can contribute to health disparities and impact progress toward health equity : better health and well-being for all.

article thumbnail

10 Ways to Leverage Buyer Signals and Drive Revenue

In today’s ultra-competitive markets, it’s no longer enough to wait for buyers to show obvious signs of interest. Instead, sales teams must be proactive, identifying and acting on nuanced buyer behaviors — often before prospects are fully ready to make a purchase. In this eBook from ZoomInfo & Sell Better, learn 10 actionable ways to use these buyer signals to transform your sales strategy and close deals faster.

article thumbnail

PAP 2023: A Summary of Unparalleled Strategies to Drive Access and Affordability

Pharmaceutical Commerce

Pharma Commerce offers a synopsis of some of the conference’s events.

Pharma 96
article thumbnail

How to Stay Compliant with State Drug Price Transparency Reporting

PM360

Drug price transparency (DPT) laws have been in effect in several states for a few years now. Starting with Vermont in 2016, more than half of the U.S. states are now collecting pricing data from manufacturers in the hopes it will assist in creating effective policies to reduce drug prices for their constituents. The question of whether this goal will be realized or not remains unanswered for now.

article thumbnail

Comparison of Humira biosimilars in the US and Europe

Pharmaceutical Technology

Biosimilars for AbbVie’s (US) Humira (adalimumab) have finally launched in the US, bringing an end to Humira’s 20-year reign as the best-selling biologic of all time. Biosimilars are an important tool to facilitate competition, lower the price of drugs, and create savings across the board. Amgen’s (US) Amjevita (adalimumab) is the first Humira biosimilar, launched in February 2023, and seven other FDA-approved biosimilars are expected to arrive on the US market later this year.

article thumbnail

A Firsthand Perspective of Pharma’s Failures with DE&I

PM360

Let’s talk digital transformation! In January, I started my series by identifying five key components of a successful digital transformation. We covered the first one by looking at Organizational Structures , today, let’s dive into the second which is the toughest, not just for pharma, but for the entire country: Diversity, Equity, and Inclusion (DE&I).

Pharma 94
article thumbnail

AI Strategies for Sales Managers: How to Cut Down on Tedious Admin Work

What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.

article thumbnail

Oncology Market Trends to Watch Out For in 2023

Medico Reach

The American Cancer Society estimates 1,958,310 new cases of cancer in the United States in 2023. As a result, a global approach to healthcare has emerged continually over the years. Even for cancers that are difficult to treat, new treatments and technologies improve patient survival rates. Hence, new oncology market trends will set in as doctors and pharmaceutical companies work towards individualized treatment decisions.

article thumbnail

Making an Impact During Disease Awareness Days, Weeks, and Months

PM360

Pharma marketers often turn to disease awareness days, weeks, and months to inform campaigns as they strategize for the year ahead. With the sheer number of official awareness days out there, it’s no wonder they’ve become a pillar to a marketer’s early plan development. To the pharma marketing industry, these days and months present a clear opportunity to shed light on a particular condition or therapeutic area.

Media 92
article thumbnail

EVERSANA® Announces Partnership with ChemoMouthpiece, LLC

PharmExec

The partnership was sealed to support U.S. launch & commercialization of a medical device to help cancer patients manage and treat oral mucositis.

article thumbnail

Oncology Market Trends to Watch Out For in 2023

Medico Reach

The American Cancer Society estimates 1,958,310 new cases of cancer in the United States in 2023. As a result, a global approach to healthcare has emerged continually over the years. Even for cancers that are difficult to treat, new treatments and technologies improve patient survival rates. Hence, new oncology market trends will set in as doctors and pharmaceutical companies work towards individualized treatment decisions.

article thumbnail

Signal-Based Selling: How to Leverage 4 Key Buying Signals

As prospects define their problem, search for solutions, and even change jobs, they are generating high-value signals that the best go-to-market teams can leverage to close more deals. This is where signal-based selling comes into play. ZoomInfo CEO Henry Schuck recently broke down specific ways to put four key buying signals into action with the experts from 30 Minutes to President’s Club.

article thumbnail

Feds to Review March-In Authority on Drug Patents

PharmaTech

A new Interagency Working Group for Bayh-Dole will review the government’s authority to revoke licenses for medical products.

Medical 52
article thumbnail

Feds to Review March-In Authority on Drug Patents

PharmExec

Amid continued tussling over drug costs, a new working group will review the government’s authority to revoke licenses for medical products.

Medical 52
article thumbnail

Curia and Corning Collaborate to Advance Biopharmaceutical Continuous-Flow Development

PharmaTech

Curia is collaborating with Corning to advance biopharmaceutical continuous-flow development and manufacturing programs.